Related Experiment Video
Updated: Jun 19, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective
Alaaeldin Shablak1, Robert E Hawkins, Dominic G Rothwell
1Department of Medical Oncology, School of Cancer, Enabling Sciences and Technology, The University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Abstract:
Metastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.
Insights
T cell-based immunotherapy shows modest success for metastatic renal cell carcinoma (MRCC). Combining tumor-infiltrating lymphocytes with lymphodepletion and identifying new antigens may improve MRCC treatment efficacy.
Area of Science:
- Oncology
- Immunology
Background:
- Metastatic renal cell carcinoma (MRCC) is difficult to treat with conventional therapies.
- Cancer immunotherapies, particularly T cell-based approaches, have shown success in melanoma.
- Renal cell carcinoma (RCC) is generally immunosensitive, but T cell therapies for MRCC have yielded limited success.
Purpose of the Study:
- To review clinical data on T cell-based immunotherapies for MRCC.
- To discuss strategies for enhancing T cell therapy efficacy in MRCC.
- To draw parallels with successful T cell-based treatments in metastatic melanoma.
Main Methods:
- Review of existing clinical data on T cell-based immunotherapies for MRCC.
- Analysis of strategies employed in melanoma immunotherapy.
- Discussion of potential improvements for MRCC treatment.
Main Results:
- Current T cell-based immunotherapies for MRCC have demonstrated modest success.
- Combining expanded tumor-infiltrating lymphocytes with lymphodepletion shows promise.
- Identifying novel RCC-associated antigens is crucial.
Conclusions:
- T cell-based immunotherapy holds potential for MRCC treatment.
- Optimizing T cell detection, isolation, modification, and expansion is essential.
- Further research into combination therapies and novel antigens is warranted for improved MRCC outcomes.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...